SeaStar Medical announces CEO Eric Schlorff will present at NobleCon21 on December 3, discussing its innovative therapies for critically ill patients.
Quiver AI Summary
SeaStar Medical Holding Corporation has announced that CEO Eric Schlorff will present at the NobleCon21 conference on December 3, 2025, in Boca Raton, Florida. The company focuses on developing treatments for critically ill patients facing organ failure, with its first commercial product, QUELIMMUNE (SCD-PED) therapy, approved by the FDA in 2024 for treating life-threatening acute kidney injury in pediatric patients. This therapy is based on the patented Selective Cytopheretic Device (SCD) technology and has received Breakthrough Device Designation for multiple conditions. SeaStar is also conducting a pivotal trial for its SCD therapy in adult patients experiencing acute kidney injury. Interested parties can register for the conference and access a presentation replay afterward on the company's website.
Potential Positives
- SeaStar Medical is participating in NobleCon21, which provides an opportunity to enhance investor visibility and attract interest from potential investors.
- The QUELIMMUNE (SCD-PED) therapy has FDA approval, making it a significant commercial product for a life-threatening condition in critically ill pediatric patients.
- The company has received Breakthrough Device Designation for six therapeutic indications, indicating strong potential for streamlined development and reimbursement advantages.
- SeaStar Medical is actively conducting a pivotal trial for its SCD therapy in adult patients, addressing a substantial unmet medical need for AKI treatment in the U.S.
Potential Negatives
- There is a lack of detailed financial information or projections, which could leave investors uncertain about the company's economic outlook and growth potential.
- The press release does not address any challenges or risks associated with the QUELIMMUNE therapy, potentially raising concerns about transparency regarding the therapy's performance or market acceptance.
- While the press release highlights the company's breakthrough designation and FDA approval, it fails to provide updates on the status of ongoing trials or the timeline for commercialization, which could leave investors questioning the progress of the company's product pipeline.
FAQ
What is SeaStar Medical Holding Corporation's focus?
SeaStar Medical is a healthcare company transforming treatments for critically ill patients facing organ failure.
When will Eric Schlorff present at NobleCon21?
Eric Schlorff will present on December 3rd at 4:00 pm Eastern Standard Time.
How can I attend the NobleCon21 presentation?
Interested attendees can register using the code ICUNOBLECON for SeaStar Medical's participation rate.
What is the QUELIMMUNE therapy?
QUELIMMUNE is SeaStar Medical’s FDA-approved therapy for life-threatening acute kidney injury in critically ill pediatric patients.
What is the status of SeaStar Medical's clinical trials?
The company is conducting a pivotal trial of its SCD therapy in adults with acute kidney injury requiring continuous renal replacement therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- HEEL KENNETH VAN has made 2 purchases buying 35,000 shares for an estimated $30,812 and 0 sales.
- JOHN NEUMAN purchased 40,000 shares for an estimated $14,396
- KEVIN CHUNG (Chief Medical Officer) purchased 10,000 shares for an estimated $8,000
- JENNIFER A BAIRD purchased 10,000 shares for an estimated $4,174
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICU Hedge Fund Activity
We have seen 10 institutional investors add shares of $ICU stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 613,241 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $261,056
- VANGUARD GROUP INC added 319,879 shares (+556.3%) to their portfolio in Q3 2025, for an estimated $182,331
- GEODE CAPITAL MANAGEMENT, LLC added 190,094 shares (+276.2%) to their portfolio in Q3 2025, for an estimated $108,353
- MILLENNIUM MANAGEMENT LLC added 179,673 shares (+inf%) to their portfolio in Q3 2025, for an estimated $102,413
- UBS GROUP AG removed 81,100 shares (-88.6%) from their portfolio in Q3 2025, for an estimated $46,226
- VIRTU FINANCIAL LLC removed 37,832 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,564
- TORONTO DOMINION BANK added 25,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,249
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 3 rd at 4:00 pm Eastern Standard Time.
Interested investors and guests of SeaStar Medical are welcome to attend the conference. Please register here using the code ICUNOBLECON for the SeaStar Medical participation rate.
A replay of the presentation will be available on Thursday, December 4 th after 4:00 pm Eastern Standard Time on the Company's website and can be accessed here . The replay will be available for up to 30 days following its posting.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
